Skip to main content
HR 4242 118th Congress House Health Administrative law and regulatory procedures Alternative treatments Department of Health and Human Services Drug therapy Drug, alcohol, tobacco use Medical research

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.

Introduced: June 21, 2023 Introduced by: Crenshaw, Dan Republican · Texas See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 23, 2023
Referred to the Subcommittee on Health.
Jun 21, 2023
Referred to the House Committee on Energy and Commerce.
Jun 21, 2023
Introduced in House
 Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.

What's happening now June 23, 2023

Referred to the Subcommittee on Health.

 Committees of jurisdiction 2
 Cosponsors 2
All 2 Democratic 1 Republican 1